Amgen's Sweeney called the results "truly remarkable." "Folks have been looking at monthly treatments ... and high-sensitivity C-reactive protein. The latter increases when there is inflammation.

Amgen UK & Ireland. “There is a vital need for novel treatments, particularly for the extensive stage of small cell lung cancer, where outcomes are especially poor,” he added. The approval is based on ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Tarlatamab is under review as a treatment for adult patients ... At the moment, Amgen looks like it has a sizeable lead in the DLL3 category, with other potential indications for tarlatamab ...

Amgen's cholesterol drug Repatha has been given ... Repatha (evolocumab) is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove LDL-C, or 'bad ...

Despite entering its maturation phase, the recombinant protein sector will continue ... inflammation and immune disorders (AIID) category includes treatments for diseases characterized by defects ...

FDA approved Amgen's Lumakras with Vectibix for KRAS ... which demonstrated that Lumakras plus Vectibix is the first and only targeted treatment combination for chemorefractory KRAS G12C-mutated ...

(RTTNews) - Amgen Inc. (AMGN), Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination therapy for the treatment of patients with KRAS G12C ...

Amgen has reported that its once-monthly dosing ... “I hope we will be the world’s first long-acting therapy in the treatment of obesity and obesity-related conditions. It's been an objective ...